BioCentury
ARTICLE | Deals

Gilead gains access to tumor myeloid targets via Pionyr partnership

Each of Gilead’s five cancer deals this year have given it a line to a new immuno-oncology approach

Sandi Wong, Assistant Editor
June 24, 2020 1:24 AM UTC


Access this Article

BCIQ Company Profiles

Gilead Sciences Inc.

Pionyr Immunotherapeutics Inc.

Next in Daily Edition for June 23, 2020

articleDealsJun 23, 2020

Vaccines deal with Sanofi to propel Translate Bio’s mRNA therapeutics platform

Expanded deal provides validation for mRNA platform, $425M up front to advance in-house pipeline

articleProduct DevelopmentJun 24, 2020

Action needed to prevent manufacturing bottlenecks on COVID-19 therapies

Urgent steps needed to prioritize, expand manufacturing capacity for most promising therapies

Data GraphicsProduct DevelopmentJun 24, 2020

Data Bytes: Roche tops list of pharmas running COVID-19 trials

articleRegulationJun 23, 2020

FDA pilot project aims to provide symptom data to cancer patients

articleRegulationJun 24, 2020

Myovant eyes third NDA for relugolix after endometriosis readout

articlePolitics, Policy & LawJun 23, 2020

Scientists warn Trump immigration ‘pause’ will harm biopharma innovation

articleTools & TechniquesJun 23, 2020

AI tools against COVID-19: a view from where the rubber hits the road

A conversation on bias, speed and accuracy in AI approaches against COVID-19

articleDealsJun 24, 2020

Gilead gains access to tumor myeloid targets via Pionyr partnership

Each of Gilead’s five cancer deals this year have given it a line to a new immuno-oncology approach

Data GraphicsDealsJun 24, 2020

Data Bytes: Gilead’s 2020 cancer deals take on immuno-oncology from different angles

articleFinanceJun 24, 2020

June 23 Quick Takes: Illumina selects first biotechs for U.K. accelerator; plus updates from the NASDAQ IPO queue, and venture rounds for Surrozen, Tara